Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 5/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10237792 | 0.89 | SLC18A3 (0.41) | SLC18A3SIGMAR1DRD4SMN1; SMN2ACHE | |
| SCHEMBL8531940 | 0.77 | DRD2 (0.42) | SLC18A3CCR8SIGMAR1CXCR3DRD4 | |
| SCHEMBL8537824 | 0.77 | DRD2 (0.42) | SLC18A3CCR8SIGMAR1CXCR3DRD4 | |
| SCHEMBL9932272 | 0.77 | DRD4 (0.41) | CCR8SIGMAR1CXCR3DRD4SMN1; SMN2 | |
| SCHEMBL8531446 | 0.77 | DRD2 (0.42) | SLC18A3CCR8SIGMAR1CXCR3DRD4 | |
| SCHEMBL8515074 | 0.77 | DRD2 (0.42) | SLC18A3CCR8SIGMAR1CXCR3DRD4 | |
| SCHEMBL22488317 | 0.69 | ALDH1A1 (0.57) | SLC18A3SIGMAR1DRD4SMN1; SMN2KDM4E | |
| SCHEMBL22488321 | 0.69 | ALDH1A1 (0.57) | SLC18A3SIGMAR1DRD4SMN1; SMN2KDM4E | |
| SCHEMBL13650590 | 0.69 | ALDH1A1 (0.57) | SLC18A3SIGMAR1DRD4SMN1; SMN2KDM4E | |
| SCHEMBL10237802 | 0.67 | DRD2 (0.43) | SLC18A3CCR8SIGMAR1DRD4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | GENENTECH, INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2012071458-A1 | HETEROCYCLIC INHIBITORS OF BETA - SECRETASE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | SLC18A3 282/4885CCR8 4797/4885SIGMAR1 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.